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Abstract
Background
The cost-effectiveness of routine viral load (VL) monitoring of HIV-infected patients on anti-
retroviral therapy (ART) depends on various factors that differ between settings and across
time. Low-cost point-of-care (POC) tests for VL are in development and may make routine
VL monitoring affordable in resource-limited settings. We developed a software tool to study
the cost-effectiveness of switching to second-line ART with different monitoring strategies,
and focused on POC-VL monitoring.
Methods
We used a mathematical model to simulate cohorts of patients from start of ART until death.
We modeled 13 strategies (no 2nd-line, clinical, CD4 (with or without targeted VL), POC-VL,
and laboratory-based VL monitoring, with different frequencies). We included a scenario
with identical failure rates across strategies, and one in which routine VL monitoring reduces
the risk of failure. We compared lifetime costs and averted disability-adjusted life-years
(DALYs). We calculated incremental cost-effectiveness ratios (ICER). We developed an
Excel tool to update the results of the model for varying unit costs and cohort characteristics,
and conducted several sensitivity analyses varying the input costs.
Results
Introducing 2nd-line ART had an ICER of US$1651-1766/DALY averted. Compared with
clinical monitoring, the ICER of CD4 monitoring was US$1896-US$5488/DALY averted and
VL monitoring US$951-US$5813/DALY averted. We found no difference between POC-
and laboratory-based VL monitoring, except for the highest measurement frequency (every
6 months), where laboratory-based testing was more effective. Targeted VL monitoring was
on the cost-effectiveness frontier only if the difference between 1st- and 2nd-line costs re-
mained large, and if we assumed that routine VL monitoring does not prevent failure.
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Conclusion
Compared with the less expensive strategies, the cost-effectiveness of routine VL monitor-
ing essentially depends on the cost of 2nd-line ART. Our Excel tool is useful for determining
optimal monitoring strategies for specific settings, with specific sex-and age-distributions
and unit costs.
Introduction
The latest World Health Organization (WHO) guidelines recommend routine viral load moni-
toring for HIV-infected patients on antiretroviral therapy (ART) in resource-limited settings
[1]. Routine viral load (VL) monitoring is the gold standard for detecting treatment failure and
deciding when patients should switch to 2nd-line ART. VL monitoring may also support adher-
ence and prevent HIV transmission, thus offering advantages beyond patient survival [2].
Most ART programs in resource-limited settings currently rely on CD4 or clinical monitoring
[3], and the debate over the long-term benefit of routine VL monitoring still continues. It cen-
ters on the high cost of VL and on the logistical constraints that may make it infeasible to im-
plement this recommendation [4–8].
We have shown that monitoring VL with a qualitative, moderately-sensitive POC VL test
benefits the patient, and may be cost-effective compared with CD4 or clinical monitoring [5].
Rapid and affordable point-of-care (POC) tests for VL are already in development [9,10]. POC
tests may improve on laboratory-based monitoring by simplifying the process. Patients could
get same-day test results, adherence counseling, and/or make treatment decisions, all during
the same visit. Though cheaper, POC tests may not be as accurate for diagnosis as sensitive and
fully quantitative tests. Nevertheless, in settings where VL monitoring is still unavailable, POC
tests may offer an affordable entry into VL monitoring.
The feasibility and cost-effectiveness of VL monitoring with a qualitative POC test depends
on many factors, and these can vary substantially among settings. We built on our earlier math-
ematical simulation model of patients on ART, to create a flexible and user-friendly tool that
allows users to evaluate the cost-effectiveness of a wide range of monitoring and switching
strategies with varying assumptions.
Methods
Simulation model
Wemodeled cohorts of HIV-infected patients from ART initiation until death. We used three
indicators to define the progression of HIV infection qualitatively: virological; immunological;
and, clinical. All three indicators have two possible values: normal and failing. We assumed
that all patients started in the normal virological, immunological and clinical stages. This repre-
sents the successful introduction of ART: VL decreases rapidly to undetectable values and re-
mains suppressed; CD4 cell count increases; and, the patient will have no more clinical (WHO
stage 3 or 4 defining) symptoms. The patient can proceed to virological failure at any time: this
represents a rebound in VL to a detectable value of>1000 copies/ml (or, at the early stages of
treatment, the failure to suppress). Progression to immunological failure represents a CD4 cell
count decline to a level that meets the WHO immunological criteria of treatment failure [1].
Progression to clinical failure represents the occurrence of WHO stage 3 or 4 defining symp-
toms. Both immunological and clinical progression can occur either as a consequence of
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virological failure (“concordant”), or independent of the patient’s virological stage (“discor-
dant”). Clinical progression also depends on the patient’s current immunological status. The
parameterization of hazard functions related to disease progression was the same as in previous
modeling studies [2,4,5], which were mostly based on two routine ART programs from the
Cape Town area, Gugulethu and Khayelitsha. The characteristics of these cohorts were de-
scribed in a previous publication [2]. The structure of the simulation model is presented in
Fig. 1 and the key parameters are listed in Table 1.
The failing virological, immunological and clinical stages will persist, unless the patient
switches to a 2nd-line ART regimen. When the patient switches, the failing virological as well as
concordant failing immunological and clinical stages will return to normal. Failing discordant
immunological and clinical stages will remain failing after switching. During 2nd-line therapy,
the patient is again at risk of proceeding to the failing virological, immunological or clinical
stage. The parameterization was the same as for 1st-line therapy, except that the risk of pro-
ceeding to virological failure was scaled up with a resistance penalty factor, which depended on
the time the patient spent on virologically failing 1st-line therapy.
Mortality consists of two components: HIV-free background mortality and HIV-related
mortality. We assumed the risk of mortality increased for patients in the failing virological, im-
munological or clinical stage. Although we assumed that all patients are retained in care from
ART initiation until death, we accounted for the expected high mortality among patients lost
to follow-up when we estimated the HIV-related mortality rates [4].
We considered a total of 13 monitoring and switching strategies (Table 2). With clinical
monitoring, the treatment failure is observed at the next regular appointment after the patient
proceeds to the advanced clinical stage, and the patient switches 3 months later. With CD4
monitoring, the failure is observed at the next appointment when the CD4 cell count is mea-
sured (which depends on the measurement frequency), and the patient switches 3 months
later. Both clinical and CD4 monitoring are assumed to be fully specific and sensitive for de-
tecting clinical or immunological failure. With routine VL monitoring, observing the failure de-
pends on the definition of failure and the test itself. With a laboratory VL test, a failure is
observed at the first monitoring appointment after the failing virological stage begins, and we
assumed that CD4s are measured simultaneously. With a qualitative POC VL test, a failure
may be observed at any visit, and the probability of detecting a failure depends on the detection
limit of the test: we assumed it was 5000 copies/ml throughout the study. The test is repeated
three months after observing the failure; if the failure is confirmed, the patient switches to
2nd-line ART. With targeted VL monitoring, only CD4 counts are measured routinely. A POC
VL test is performed immediately if an immunological failure is detected. If this test is also pos-
itive, a second VL test is performed 3 months later.
We modeled two scenarios. In Scenario A, we assumed that the risk of treatment failure did
not depend on the monitoring and switching strategy, and thus, for all strategies, we used the
rates estimated from the South African data (where VL is monitored regularly). In Scenario B,
we assumed that VL monitoring can prevent treatment failure, and that the South African rates
underestimate the risk in strategies where VL monitoring is unavailable. We assumed this be-
cause routine viral load monitoring can detect poor adherence. Many patients with a detectable
viral load can re-suppress viral load on first-line ART, after an adherence intervention [11–14].
Since poor adherence is a major predictor of treatment failure [15,16], routine viral load moni-
toring may prevent treatment failures caused by poor adherence. For these strategies, we as-
sumed that the hazard would be twice as high across the entire follow-up period.
The model was constructed in three steps. In the first step, we simulated cohorts of 100,000
patients for all 13 monitoring and switching strategies, without baseline characteristics or back-
ground mortality. We implemented the model using ‘gems’, an R package for generalized
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multistate simulation models [17,18]. ‘Gems’ models disease progression as a series of events
(e.g., diagnosis, treatment and death) that can be displayed in a directed acyclic graph (DAG).
The vertices correspond to disease states and the directed edges represent events. Similar mod-
els that use the package ‘gems’ or a similar algorithm have been published elsewhere [2,4,5,19].
For strategies without routine VL monitoring we modeled two cohorts with different failure
rates (scenarios A and B). This resulted in a total of 20 cohorts.
Fig 1. Progression of patients in the mathematical model. Panel A shows the progression of the patient’s treatment regimen and observed failure status.
Within each compartment of panel A, the patient will proceed according to the underlying treatment progression shown in Panel B. The type of failure that can
be detected depends on the monitoring strategy. After switching to second-line therapy, the patient will start either in the successful ART compartment (if he/
she had no or concordant immunological/clinical failure) or in the clinical and/or immunological failure compartment (if he/she had a discordant failure of the
corresponding type). See the main text for definitions of concordant and discordant failures.
doi:10.1371/journal.pone.0119299.g001
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Table 1. Key parameters related to disease progression.
Outcome Source Statistical model Starting Value (95%
CI)
Dimension Risk
1) Time to virological failure
(a) First-line ART; second-line
ART with immediate switch
Cohorts Parametric Weibull 3 months from ART
start/switch
0.57 (0.52–
0.63)
Shape 3.4% fail by 1 year
after ART start
2.75 (2.29–
3.31)
Scale (100
years)
(b)Resistance penalty [37] * n/a 0.05 (0.00–
0.20)
Decrease in
efﬁcacy
n/a
2) Time to immunological failure
(a) After virologic failure Cohorts Parametric exponential Virological failure 0.08 (0.06–
0.10)
Rate (years-1) 7.6% fail by 1 year
after virologic failure
(b) Independently of virologic
failure
Cohorts Parametric Weibull 3 months from ART
start
0.22 (0.20–
0.25)
Shape 3.0% fail by 1 year
after ART start
5.46 (3.14–
9.51)
Scale (106
years)
3) Time to clinical failure
(a)Without virologic or
immunologic failure
[6] Parametric exponential ART start 0.004 Rate (years-§) 0.4% fail by 1 year
after ART start
(b) Extra hazard after
immunologic failure
[6,38] Cox regression Immunologic failure 3.3 HR, constant
over time
n/a
(c) Extra hazard after virologic
failure
[6] Cox regression Virologic failure 2 HR, constant
over time
n/a
4) Time to death (HIV-related mortality)
(a) Observed mortality Cohorts No speciﬁc model
(competing risk
analysis)
ART start ** n/a 6.5% die by 1 year
after ART start
(b) Observed LTFU Cohorts No speciﬁc model
(competing risk
analysis)
ART start ** n/a 4.0% lost by 1 year
after ART start
(c) Mortality among LTFU Analysis 4b,
[39]
No speciﬁc model
(theoretical calculation)
n/a ** n/a n/a
(d) HIV-related mortality Analyses 4a-
4c
Theoretical calculation,
double Weibull***
ART start 0.88 (0.88–
0.90)
Shape 1 8.8% die by 1 year
after ART start
0.35 (0.32–
0.39)
Scale 1 (years)
1.00 (1.00–
1.00)
Shape 2
64.60
(54.52–
76.55)
Scale 2 (years)
0.08 (0.08–
0.08)
Weight (1st
component)
(a) Extra hazard after clinical
failure
assumption Cox regression Clinical failure 2 HR, constant
over time
n/a
(b) Extra hazard after
immunologic failure
Cohorts Cox regression Immunologic failure 1.76 (1.16–
2.68)
HR, constant
over time
n/a
(Continued)
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In the second step, these cohorts were updated to account for differences in background
mortality. Thirty-two copies of each of the 20 cohorts were created, for the different sexes
(male and female), baseline age groups (15–24, 25–34, 35–44 and 45–54 years), and four differ-
ent scenarios of background mortality. In the first three scenarios, the background mortality
rates represent the overall HIV-free mortality in the general populations of Malawi and Zimba-
bwe [20], and in Africans in the Western Cape [21]. In the fourth scenario, we assumed that
the HIV-free life expectancy from birth would be 75 years for all patients. Each patient was
assigned an age, sampled from a uniform distribution within the given range. A time of HIV-
unrelated death was sampled for each patient, based on the gender, baseline age and the back-
ground mortality rate.
In the third step, we analyzed the outcomes of interest. The main outcomes were disability-
adjusted life-years (DALY) lost to HIV, total cost, and cost-effectiveness ratios of the interven-
tion compared to current practice as well as to the next less expensive strategy (incremental
cost-effectiveness ratio, ICER). Definitions are given in S1 Text.
Excel tool
We developed an Excel spreadsheet tool to adapt the model outputs to specific scenarios. The
Excel table contains all outputs of the simulation and presents the results according to the sce-
nario defined by the user. The user can vary the following input variables continuously
(Table 3): size of cohort; unit costs for clinic visit, VL and/or CD4 test, one year of 1st- and 2nd-
line ART; and, disability weight of symptomatic and asymptomatic HIV. The user can specify
the age and gender distribution of the cohort by giving proportions for each of the eight age
and gender groups. Finally, the user can specify the failure rate scenario (A or B), background
mortality (Malawi, Zimbabwe, Western Cape, or constant life expectancy 75 years) and dis-
counting (0%, 1%, 2%, 3%, 4%, or 5%). The main results are then updated based on the as-
sumptions. The Excel table also shows the ICERs, and graphically presents the costs and
averted DALYs of each scenario.
We present the results in this manuscript for a set of input parameters (Table 3). We as-
sumed the costs of 1st-line ART were US$99/year and 2nd-line ART were US$280/year. VL
Table 1. (Continued)
Outcome Source Statistical model Starting Value (95%
CI)
Dimension Risk
(c) Extra hazard after virologic
failure
Cohorts Cox regression Virologic failure 1.26 (0.86–
1.85)
HR, constant
over time
n/a
The hazard of virological failure (1a) is applied for ﬁrst-line ART as such, and for second-line ART together with a resistance penalty factor (1b) which
depends on the time spent on failing ﬁrst-line ART. Immunological failure can happen through two independent hazard functions: the other is applied only
to patients on virologically failing ﬁrst- or second-line ART (2a), the other for all patients irrespective of the virological status or ART regimen (2b). For
clinical failure, the hazard function (3a) is used as such for patients without virological and immunological failures, and the hazard ratios (3b, 3c) are
applied for patients with the corresponding failures. HIV-related mortality is calculated from a competing risk analysis of observed mortality (4a) and loss to
follow-up (4b) as well as the expected mortality among lost patients (4c). The parametric hazard function for mortality (4d) is used as such for patients
without virological, immunological or clinical treatment failure, and the hazard ratios (4e, 4f, 4g) are applied to patients with the corresponding failures.
CI, conﬁdence interval; ART, antiretroviral therapy; HR, hazard ratio; LTFU, loss to follow-up; n/a, not applicable
* Relative decrease in second-line efﬁcacy per year spent on failing ﬁrst-line ART
** Observed mortality and LTFU rates on successful ﬁrst-line ART were calculated from the data and used, together with background mortality and
expected mortality among patients LTFU, to calculate the corrected HIV-related mortality for the cohort
***Weighted sum of two Weibull distributions
doi:10.1371/journal.pone.0119299.t001
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tests (both POC and laboratory-based) were assumed to cost US$10, and CD4 tests US$5. We
did not consider the cost of clinic appointments. Disability coefficients were 0.135 for asymp-
tomatic HIV and 0.369 for symptomatic HIV. The disability coefficient for symptomatic HIV
was the product of the coefficients of asymptomatic HIV and tuberculosis, the most common
opportunistic infection [22]. All results are presented per one patient. Costs and DALYs are
discounted annually by 3%. Two separate analyses were conducted: one in which virological
failure rates were identical (Scenario A); and one in which it was twice as high in strategies
without routine VL monitoring than in strategies with routine VL monitoring (Scenario B).
We also present 10 sensitivity analyses in the S2 Text and S1 Table, in which the unit costs of
tests and ART and the discounting rate were varied.
Table 2. Monitoring strategies.
Strategy Visits CD4 tests VL tests Switching criteria
1. No 2nd-line ART
1.1 No 2nd-line ART every 3
months*
no no no
2. Clinical monitoring
2.1 Clinical monitoring every 3 months no no WHO clinical criteria
3. CD4-based monitoring
3.1 Irregular CD4 monitoring
6m
every 3
months*
every 6
months**
no 2x WHO immunological criteria
3.2 CD4 monitoring 24m every 3
months*
every 24 months no 2x WHO immunological criteria
3.3 CD4 monitoring 12m every 3
months*
every 12 months no 2x WHO immunological criteria
3.4 CD4 monitoring 6m every 3
months*
every 6 months no 2x WHO immunological criteria
3.5 CD4 6m + tVL monitoring every 3
months*
every 6 months POC after CD4 failure WHO immunological criteria + 2x VL5000 copies/
ml
4. Point-of-care viral load monitoring
4.1 POC-VL monitoring 24m every 3
months*
no POC every 24
months
2x VL5000 copies/ml
4.2 POC-VL monitoring 12m every 3
months*
no POC every 12
months
2x VL5000 copies/ml
4.3 POC-VL monitoring 6m every 3
months*
no POC every 6 months 2x VL5000 copies/ml
5. Laboratory-based viral load monitoring
5.1 Lab VL monitoring 24m every 3
months*
every 24
months*
Lab every 24 months 2x VL1000 copies/ml
5.2 Lab VL monitoring 12m every 3
months*
every 12
months*
Lab every 12 months 2x VL1000 copies/ml
5.3 Lab VL monitoring 6m every 3
months*
every 6 months* Lab every 6 months 2x VL1000 copies/ml
ART, antiretroviral therapy; VL, viral load; tVL, targeted viral load; m, monthly; POC, point-of-care; Lab, laboratory-based
POC VL tests are assumed to be qualitative with a detection limit of 5000 copies/ml; lab-VL tests are assumed to be fully quantitative
2x = second conﬁrmatory measurement 3 months after ﬁrst observation needed
* The information from these visits/tests is not used to decide about switching to second-line
** The probability of having a test is 50%
doi:10.1371/journal.pone.0119299.t002
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Results
Excel tool
The Excel tool is presented in S1 Excel File.
Scenario A: Failure rate is identical in all monitoring and switching
strategies
In the absence of 2nd-line and monitoring, the average lifetime cost of ART was US$1419 per
patient (Table 4). On average, each patient lost 7.3 DALYs to HIV. Adding 2nd-line ART with
clinical monitoring (2.1) increased the costs to US$1563 per patient and averted 0.09 DALYs.
The costs of strategies with CD4 monitoring ranged from US$1690 (3.2) to US$1812 (3.5).
CD4 monitoring averted 0.05 to 0.09 DALYs more than clinical monitoring: the benefit was
higher for Strategies 3.1 and 3.5 than for Strategies 3.2, 3.3 and 3.4. Targeted VL monitoring
(3.5) cost, on average, an additional US$12 per patient, but saved about US$61 per patient for
ART over the same strategy without VL tests (3.4) by not switching of patients with suppressed
Table 3. Input parameters that can be varied using the Excel tool.
Input Value for main analysis Values for sensitivity
analyses
Values included in the Excel tool
Costs
Visit Not included Not included 0 to inﬁnity
CD4 test US$ 5 US$ 2 0 to inﬁnity
POC viral load test US$ 10 US$ 5, US$ 7, US$ 15 0 to inﬁnity
Laboratory viral load test US$ 10 US$ 5, US$ 7, US$ 15 0 to inﬁnity
1st-line ART per year US$ 99 US$ 55, US$ 128 0 to inﬁnity
2nd-line ART per year US$ 280 US$ 140, US$ 210, US$
350
0 to inﬁnity
Disability coefﬁcients
Asymptomatic HIV 0.135 - 0 to 1
Symptomatic HIV 0.369 - 0 to 1
Size of cohort
Size of cohort 1 - 1 to inﬁnity
Discounting
Annual discounting rate 3% 0% 0%, 1%, 2%, 3%, 4%, 5%
Age and gender distribution
Proportion of each age-gender
group
1% M15–24; 8% F15–24; 12% M25–34; 35%
F25–34; 14% M35–45; 18% F35–44; 6% M45–
54; 6% F45–54
- 0 to 100% in any group, summing to
100%
Background mortality
HIV-unrelated mortality ASSA2008 (Africans in Western Cape) - GBD Malawi; GBD Zimbabwe;
ASSA2008 Africans in Western
Cape; 75 years*
Virological failure rate
Virological failure rate in strategies
without viral load monitoring (1.1–
3.5)
Identical to strategies 4.1–5.3 (see Table 2 for
the parameters)
Twice as high compared
to strategies 4.1–5.3**
Identical or twice as high compared
to strategies 4.1–5.3
ART, antiretroviral therapy; US$, US dollar; M, male; F, female; GBD, Global Burden of Disease study; ASSA2008, ASSA2008 model
* Every simulated patient dies at the age of 75 if the effect of HIV is not accounted for
** This analysis is presented as the second main analysis, not a sensitivity analysis
doi:10.1371/journal.pone.0119299.t003
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VLs. The total costs for strategies with VL monitoring ranged from US$1840 (4.1) to US$2216
(5.3). VL monitoring averted 0 to 0.05 DALYs more than the most effective CD4 monitoring
strategy (3.5), and 0.09 to 0.14 more than clinical monitoring (2.1). There were no clear differ-
ences between POC and laboratory-based VL monitoring in the number of averted DALYs.
The POC VL strategy with most frequent (every 6 months) monitoring (4.2) averted slightly
fewer DALYs than POC VL monitoring every 12 months (4.3).
No 2nd-line (1.1), clinical monitoring (2.1), irregular CD4 monitoring every 6 months (3.1),
CD4 monitoring every 6 months with targeted VL monitoring (3.5), and POC VL monitoring
every 12 months (4.2) were on the cost-effectiveness frontier (Fig. 2A). The cost-effectiveness
ratio of clinical monitoring alone (2.1) compared with no 2nd-line (1.1) was US$1651/DALY
averted. Compared with clinical monitoring alone (2.1), CD4 monitoring averted a DALY at
costs betweenUS$2123 (3.1) and US$5488 (3.5). VL monitoring strategies prevented a DALY
at costs between US$3478 (4.1) and US$33515 (4.3) as compared with Strategy 3.1 or US$2494
(4.1) to US$813 (4.3) as compared with Strategy 2.1.
Scenario B: Failure rate is twice as high without VL monitoring as with VL
monitoring
When only 1st-line ART was available (1.1), the average lifetime cost of ART was US$1401 per
patient (Table 5). On average, each patient lost 7.5 DALYs to HIV. When 2nd-line ART with
clinical monitoring was added (2.1), this increased the costs to US$1569 per patient and
Table 4. Model outcomes: main analysis assuming the treatment failure rate to be identical in all strategies.
Strategy No 2nd-l. Clinical CD4 monitoring POC-VL monitoring Lab-VL monitoring
1.1 2.1 3.1 3.2 3.3 3.4 3.5 4.1 4.2 4.3 5.1 5.2 5.3
Life-years
Healthy life-years left 19.5 19.5 19.5 19.5 19.5 19.5 19.5 19.5 19.5 19.5 19.5 19.5 19.5
Life-years on 1st-line ART 14.3 13.7 13.3 13.3 13.2 13.2 13.6 12.7 12.7 12.5 12.8 12.7 12.7
Life-years on 2nd-line ART 0.0 0.8 1.3 1.2 1.3 1.3 0.9 1.8 1.9 2.0 1.8 1.9 1.9
Life-years without symptoms 13.6 13.8 13.8 13.8 13.8 13.8 13.8 13.9 13.9 13.9 13.9 13.9 13.9
Life-years with symptoms 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7
Life-years lost to HIV 5.2 5.1 5.0 5.0 5.0 5.0 5.0 5.0 4.9 5.0 5.0 5.0 4.9
Disability-weighted life-years 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1
DALYs lost to HIV 7.3 7.2 7.1 7.1 7.1 7.1 7.1 7.1 7.1 7.1 7.1 7.1 7.1
Costs
Cost of 1st-line ART 1419 1353 1313 1313 1306 1304 1347 1261 1254 1238 1263 1256 1255
Cost of 2nd-line ART 0 211 351 341 363 365 259 507 534 563 499 521 530
Cost of diagnostic tests 0 0 71 36 72 143 156 73 147 292 107 216 431
Total costs 1419 1564 1735 1690 1741 1812 1761 1840 1935 2094 1869 1993 2216
Cost-effectiveness
CER compared to 1.1 l/e 1651 1877 1967 2243 2959 1910 2122 2304 3775 2359 2844 3585
ICER l/e 1651 2123 w/d s/d s/d 2418 w/d 3872 s/d s/d s/d s/d
Please see Table 2 for a detailed description of all monitoring strategies. All costs are given in US$ and cost-effectiveness ratios in US$ per
DALY averted.
POC-VL, point-of-care viral load; lab-VL, laboratory-based viral load; ART, antiretroviral therapy; DALY, disability-adjusted life-year; CER, cost-
effectiveness ratio; ICER, incremental cost-effectiveness ratio; l/e, least expensive and least effective strategy; w/d, weakly dominated; s/d,
strongly dominated.
doi:10.1371/journal.pone.0119299.t004
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averted 0.10 DALYs. CD4 monitoring strategies cost between US$1794 (3.2) and US$1929
(3.4). CD4 monitoring averted 0.10 to 0.12 DALYs more than clinical monitoring: the benefit
increased with monitoring frequency and was highest for targeted VL monitoring. Targeted
VL monitoring (3.5) cost, on average, an additional US$13 per patient, but ART cost about US
$58 less per patient than in Strategy 3.4, because patients with suppressed VLs did not need to
be switched. The results of strategies that used VL monitoring (4.1 to 5.3) are the same as those
in Scenario A.
Except for the no 2nd-line strategy (1.1), only POC VL monitoring every 24 (4.1) and 12
months (4.2) were on the cost-effectiveness frontier (Fig. 2B). Clinical monitoring was weakly
dominated by POC VL monitoring every 24 months. Strategies based on CD4 monitoring cost
about as much as those that used VL monitoring, but averted fewer DALYs. The cost-effective-
ness ratio of clinical monitoring alone (2.1) compared with no 2nd-line (1.1) was US$1766/
DALY averted. Compared with clinical monitoring alone (2.1), CD4 monitoring averted a
DALY at costs between US$1896 (3.5) and US$2540 (3.1). VL monitoring strategies prevented
a DALY at costs between US$48 (4.1) and US$1875 (5.3) as compared with Strategy 3.1 or US
$951 (4.1) and US$2097 (5.3) as compared with Strategy 2.1.
Fig 2. Cost-effectiveness of different monitoring strategies for antiretroviral therapy. Panel A presents Scenario A (failure rate identical in all
monitoring strategies). Panel B presents Scenario B (failure rate twice as high in strategies without compared to strategies with routine viral load monitoring).
Cost and DALYs averted are presented per one patient for the duration of ART. Please see Table 2 for a detailed description of the monitoring strategies.
doi:10.1371/journal.pone.0119299.g002
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Table 5. Model outcomes: main analysis assuming that treatment failure rate is twice as high in strategies without routine viral load monitoring
(1.1 to 3.5) as in strategies with routine viral load monitoring due to improved adherence.
Strategy No 2nd-l. Clinical CD4 monitoring POC-VL monitoring Lab-VL monitoring
1.1 2.1 3.1 3.2 3.3 3.4 3.5 4.1 4.2 4.3 5.1 5.2 5.3
Life-years
Healthy life-years left 19.5 19.5 19.5 19.5 19.5 19.5 19.5 19.5 19.5 19.5 19.5 19.5 19.5
Life-years on 1st-line ART 14.2 13.3 12.5 12.5 12.4 12.4 12.8 12.7 12.7 12.5 12.8 12.7 12.7
Life-years on 2nd-line ART 0.0 0.9 1.9 1.9 2.0 2.0 1.7 1.8 1.9 2.0 1.8 1.9 1.9
Life-years without symptoms 13.3 13.5 13.6 13.6 13.7 13.7 13.7 13.9 13.9 13.9 13.9 13.9 13.9
Life-years with symptoms 0.8 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7
Life-years lost to HIV 5.4 5.3 5.2 5.1 5.1 5.1 5.1 5.0 4.9 5.0 5.0 5.0 4.9
Disability-weighted life-years 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1
DALYs lost to HIV 7.5 7.4 7.3 7.3 7.2 7.2 7.2 7.1 7.1 7.1 7.1 7.1 7.1
Costs
Cost of 1st-line ART 1401 1320 1234 1237 1228 1228 1263 1261 1254 1238 1263 1256 1255
Cost of 2nd-line ART 0 249 527 521 547 558 466 507 534 563 499 521 530
Cost of diagnostic tests 0 0 70 36 72 143 156 73 147 292 107 216 431
Total costs 1401 1569 1831 1794 1848 1929 1884 1840 1935 2094 1869 1993 2216
Cost-effectiveness
CER compared to 1.1 l/e 1766 2168 1947 2102 2199 1849 1156 1317 1924 1258 1545 2019
ICER l/e w/d s/d w/d s/d s/d s/d 1156 3715 s/d s/d s/d s/d
Please see Table 2 for a detailed description of all monitoring strategies. All costs are given in US$ and cost-effectiveness ratios in US$ per
DALY averted.
POC-VL, point-of-care viral load; lab-VL, laboratory-based viral load; ART, antiretroviral therapy; DALY, disability-adjusted life-year; CER, cost-
effectiveness ratio; ICER, incremental cost-effectiveness ratio; l/e, least expensive and least effective strategy; w/d, weakly dominated; s/d,
strongly dominated.
doi:10.1371/journal.pone.0119299.t005
Table 6. Cost-effectiveness of 12-monthly point-of-care viral load monitoring (strategy 4.2) compared with clinical monitoring (strategy 2.1),
assuming that the risk of virological failure is either identical in both strategies (Scenario A) or twice as high with viral load monitoring than
with clinical monitoring (Scenario B).
Analysis Varied input value Cost-effectiveness ratio (US$/DALY averted)
Scenario A Scenario B
Main 2723 1180
VL1 Cost of VL test: US$7 2400 1037
VL2 Cost of VL test: US$5 2184 942
VL3 Cost of VL test: US$15 3262 1417
FL1 Cost of 1st-line ART: US$55/year 3045 1275
FL2 Cost of 1st-line ART: US$128/year 2511 1117
SL1 Cost of 2nd-line ART: US$210/year 2131 950
SL2 Cost of 2nd-line ART: US$140/year 1539 720
SL3 Cost of 2nd-line ART: US$350/year 3315 1409
DI1 No discounting 2015 892
All performed sensitivity analyses are listed in S1 Table and their full results in S2 to S11 Tables of the Supplementary Material. The results of Analysis
CD1 are not shown since the cost of CD4 test does not inﬂuence either strategy. The input values used in the main analysis are shown in Table 3.
doi:10.1371/journal.pone.0119299.t006
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Sensitivity analyses
The results of the sensitivity analyses are presented in detail in Table 6 and S2 Text and S2 to
S11 Tables. Of note is the dependence of the benefit of targeted routine VL monitoring on the
ratio of the costs between 1st- and 2nd-line regimens. If the prices of 1st- and 2nd-line regimens
were similar, targeted VL monitoring was dominated; if 2nd-line ART was assumed to be sub-
stantially more expensive, targeted VL monitoring was on the cost-effectiveness frontier.
Discussion
We simulated cohorts of patients who initiated ART under 13 different ART monitoring and
switching strategies. VL monitoring was slightly more effective than CD4 monitoring (in par-
ticular if we assumed that VL monitoring also reduces the risk of treatment failure). CD4 mon-
itoring was more effective than clinical monitoring, and clinical monitoring was more effective
than 1st-line ART only. However, differences in the effectiveness of any two strategies were all
below 1 DALY per patient. We observed no clear difference between monitoring strategies that
measured at different intervals, or between VL monitoring that used fully quantitative, highly
specific and sensitive laboratory tests or those that used a qualitative POC test. The cost-effec-
tiveness of POC VL monitoring clearly improved if we reduced the gap between prices of 1st-
and 2nd-line ART (Table 6).
Across our analyses, 12-month routine POC VL monitoring was on the cost-effectiveness
frontier. The cost-effectiveness ratio of this strategy compared to clinical monitoring varied be-
tween US$700 and US$3300 per DALY averted. Cost-effectiveness improved if we assumed
that VL monitoring reduces the risk of failure, and when the price of 2nd-line ART and 1st-line
ART were close. The cost-effectiveness ratio of US$700 per DALY averted was reached if 2nd-
line costs were reduced to minimum and we assumed that routine VL monitoring prevents fail-
ure. If we define a cost-effective intervention as having a cost-effectiveness ratio of less than
3 times the local per-capita gross domestic product, a cost-effectiveness ratio of US$700 per
DALY averted can be considered cost-effective in any country [23,24]. We found no major dif-
ferences between fully quantitative laboratory-based VL monitoring with CD4 tests, and quali-
tative POC VL monitoring. The potential disadvantage of a POC test that we assumed was the
possibility of “false positive” switches to 2nd-line ART, i.e. switching patients who do not have a
persistent detectable viral load. For example, if a patient has two successive detectable viral
load values, and if the exact values of the VLs and the CD4 cell count are known, the clinician
may be able to distinguish a patient failing therapy and a patient with blips, poor adherence,
measurement errors, etc. The qualitative test only gives a positive or negative result, upon
which a decision must be based. Although we did not find differences between laboratory-
based and POC VL monitoring overall, increasing the frequency of POC VL monitoring from
12 to 6 months slightly decreased, rather than increased life-years. This was not the case for
laboratory-based VL monitoring. We think this is caused by false positive failures with POC
tests: increasing the measurement frequency increases the number of patients who switch un-
necessarily, and this may affect their future treatment options.
The cost-effectiveness of targeted VL monitoring varied changed with the input parameters.
We found that if the price of 2nd-line ART is considerably higher than for 1st-line ART, and if
we assume no additional benefits for routine VL monitoring, it may be cost-effective to con-
duct routine CD4 monitoring with targeted VL testing. This strategy uses routine CD4 tests to
detect patients who may be on a failing 1st-line regimen. Patients are then given VL tests to
confirm their status. This strategy reduces the total costs by restricting use of 2nd-line ART to
patients who need it most (those with low CD4 cell counts and a high risk of mortality), and by
not switching patients with suppressed VLs. However, if we assume that routine VL
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monitoring can also reduce the risk of failure, for example, or if the cost difference between the
regimens is small, routine VL monitoring is preferable.
Optimal monitoring strategy has been investigated in a number of mathematical modeling
studies. Walensky et al published a review of five modeling studies that assessed the cost-
effectiveness of different strategies for monitoring HIV-infected patients on ART [25]. Four of
the models investigated VL monitoring [6,26–28]. After the review was published, similar
modeling studies have appeared [29,30]. A recent article [31] systematically compared three
models. All these studies suggest that VL monitoring may moderately improve the outcomes of
ART programs, but cost-effectiveness estimates vary substantially between them. The variance
may be caused by the different assumptions in the input values. We believe our study is the
first to include a tool that allows users to easily vary input values.
Limitations
Our analysis has several limitations. First, we only included time on ART. Diagnostic tests,
and, in particular, CD4 cell counts, are usually recommended for monitoring patients before
ART is initiated. If assessment of ART eligibility continues to depend on CD4 cell counts, CD4
monitoring will continue to be important. However, there is a growing tendency towards sim-
pler rules for ART initiation, such as “Option B+”, in which all pregnant and breastfeeding
women start lifelong ART [32], or universal “test and treat” [33]. We anticipate that, in many
settings, there will be a decreased need to measure CD4 cell count to assess eligibility for ART.
However, to estimate the true costs of CD4 testing, the use of CD4 cell measurements for pur-
poses other than on-treatment monitoring must be taken into consideration. The usefulness of
monitoring immune response by CD4 cell measurement during the first year of ART should
also be evaluated.
We did not include loss to follow-up (LTFU). High rates of LTFU are a serious problem in
most ART programs in resource-limited settings [34]. LTFU is a combination of unregistered
deaths, unregistered transfers, and cases in which a patient has stopped ART [35]. We took the
effect of LTFU on mortality into account in the parameterization of mortality. Patients who
transferred to another ART clinic can be expected to take ART as recommended. We did not
take include the effect of patients who stopped ART. POC monitoring may offer advantages
over laboratory-based monitoring by making it easier to manage patients and by shortening
wait times. This may, in turn, improve retention [36], and is another argument for POC moni-
toring, but it is not studied in the current analysis.
We did not model onward transmission. VL monitoring reduces the time the patient spends
on a failing regimen. VL monitoring can prevent about 30% of transmissions from patients on
treatment [2,5], and this may substantially improve the cost-effectiveness of VL monitoring.
Therefore, the long-term population-level benefits of VL monitoring may be larger than
we estimated.
We assumed that laboratory-based VL monitoring, together with CD4 tests, is 100% sensi-
tive and specific to detect true treatment failure. Although this is a simplifying assumption, we
wanted to include two distinct types of viral load test: one of these is as accurate as possible,
and one has a lower sensitivity and specificity. The POC tests were assumed to be neither fully
sensitive nor specific to detect true treatment failure. The users of the Excel tool can therefore
choose either laboratory-based or POC viral load monitoring, depending on the diagnostic ca-
pacities of the viral load test they want to investigate. We also assumed CD4 tests are fully sen-
sitive and specific. But since CD4 cell count poorly predicts true treatment failure, this
assumption should not have much effect on the results.
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The Excel tool allows users to vary input costs and several other input parameters. However,
parameters related to disease progression cannot be changed in the Excel tool. Most key pa-
rameters for HIV progression are based on two large ART cohorts from the Cape Town area:
Gugulethu and Khayelitsha. The results of the model reflect the characteristics of these routine
ART programs, typical of southern Africa: the majority of patients are women, and most pa-
tients start ART with low CD4 cell counts and advanced clinical symptoms. We believe the re-
sults of our model can be generalized widely for ART programs in sub-Saharan Africa.
However, there are also important differences between the cohorts we drew on, and others: the
Cape Town cohorts had access to frequent laboratory measurements, and there is a continuous
tendency to start ART earlier. Our model may not be able to catch all site-level characteristics
of the different settings.
Conclusion
POC VL testing appears to be a promising alternative for routinely monitoring ART in re-
source-limited settings, especially if we assume that viral load monitoring can prevent treat-
ment failure by improving adherence, and that the gap between prices of 1st- and 2nd-line ART
can be decreased. Under these conditions, VL monitoring every 12 or 24 months, with an af-
fordable qualitative test, does not considerably increase the costs above those of CD4 monitor-
ing. POC VL testing may offer the same benefit as frequently monitoring VL with a
quantitative test. Routine VL monitoring may also have benefits beyond more accurate detec-
tion of treatment failure; it may for example be able to prevent treatment failure by improved
adherence. Targeted VL monitoring, based on routine CD4 monitoring, may be an option if
these potential benefits are small, if 2nd-line ART remains substantially more expensive than
1st-line ART, and if it is expected that 2nd-line ART cannot be provided for everyone failing vi-
rologically. Special attention should be paid to the price of 2nd-line ART, which we expect will
play a more substantial role than the price of the diagnostic tests. To make routine viral load
monitoring cost-effective, efforts must be made to drop the costs of 2nd-line antiretroviral
drugs. The optimal monitoring and switching strategy for each setting depends substantially
on factors such as the unit costs. Our Excel tool allows researchers and policy-makers to vary
important cost and population structure parameters and may be a valuable tool for developing
local monitoring guidelines.
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